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Abstract 
Aims. The aim of this study was to evaluate the in‐hospital and 1‐year prognostic impact of diabetes and elevated 
blood glucose levels at hospital admission in patients with acute heart failure (HF). 
Methods and results. We studied a multinational cohort of 6926 hospitalized patients with acute HF enrolled in the 
European Society of Cardiology (ESC) and Heart Failure Association (HFA) Long‐Term Registry, of whom 49.4% 
(n = 3422) had known or previously undiagnosed diabetes (defined as self‐reported history, or medication use, or 
fasting glucose levels ≥7.0 mmol/L or haemoglobin A1c ≥6.5%). Compared with those without diabetes, patients with 
known or previously undiagnosed diabetes had higher cumulative rates of in‐hospital mortality, 1‐year mortality, and 
1‐year HF re‐hospitalization that occurred independently of multiple clinical risk factors: in‐hospital mortality [6.8 
vs. 4.4%; adjusted hazard ratio (HR) 1.774; 95% confidence interval (CI) 1.282–2.456, P < 0.001], 1‐year all‐cause 
mortality (27.5 vs. 24%; adjusted HR 1.162; 95% CI 1.020–1.325, P = 0.024), and 1‐year hospital re‐admissions for 
HF (23.2 vs. 18.5%; adjusted HR 1.320; 95% CI 1.139–1.530, P < 0.001). Moreover, elevated admission blood 
glucose concentrations were powerfully prognostic for in‐hospital mortality, but not for 1‐year mortality or re‐
hospitalizations, in both patients with and without diabetes.  
Conclusions. Among patients hospitalized for acute HF, the presence of diabetes is independently associated with an 
increased risk of in‐hospital mortality, 1‐year all‐cause mortality, and 1‐year re‐hospitalizations for HF, underscoring 
the need for more effective and personalized treatments of diabetes in this particularly high‐risk patient population. 
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Introduction 
Diabetes mellitus and heart failure (HF) are two common diseases that often co‐exist. The prevalence 
of diabetes among patients with HF is extremely high, and it has been estimated as between 30% and 
50%.
1-3
 More than 40 years ago, the Framingham Heart study first reported that the risk for new‐onset HF 
in patients with diabetes was about two‐fold higher in men and five‐fold in women compared with 
individuals without diabetes.
4
 The pathogenesis of HF in diabetes is multifactorial, but can be largely 
attributed to ischaemic heart disease, hypertension, diabetic cardiomyopathy, and extracellular fluid 
volume expansion.
1, 2
 Remarkably, diabetes per se is a significant risk factor for new‐onset HF, 
independent of hypertension and ischaemic heart disease, suggesting that glycaemic control may 
influence the development of new‐onset HF.5 Recently, in response to concerns about the cardiovascular 
safety of rosiglitazone, a number of large randomized clinical trials have been designed to evaluate the 
cardiovascular safety of the newer drugs for the treatment of type 2 diabetes. To date, no new sound 
adverse cardiovascular safety signal (including the risk for HF) has arisen from the trials with incretin‐
based therapies (i.e. dipeptidyl peptidase 4 inhibitors and glucagon‐like peptide 1 receptor agonists), and 
there is now evidence of benefit from the EMPA‐REG trial with empagliflozin, a sodium–glucose co‐
transporter 2 inhibitor.
5, 6
 
 
Despite the known high prevalence of diabetes among patients with HF, there are few contemporary, 
comparative data on the in‐hospital and post‐discharge survival outcomes from multinational cohorts of 
patients with and without diabetes who have been acutely admitted to the hospital for HF, out of the 
context of randomized clinical trials. Additionally, while diabetes is associated with increased mortality 
and morbidity in ambulatory patients with chronic systolic HF,
1, 2
 its influence as an independent 
predictor of in‐hospital and post‐discharge adverse outcomes after hospitalization for acute HF is not 
consistently apparent. In fact, the published studies of patients hospitalized for HF that have explored the 
impact of diabetes per se on in‐hospital and post‐discharge clinical outcomes in patients hospitalized for 
acute HF have reported conflicting results, suggesting the need for further studies.  
 
Indeed, as will be discussed in detail below, some large registry databases and clinical trials have 
shown that diabetes was associated with either poorer in‐hospital and post‐discharge survival outcomes or 
higher 1‐year re‐hospitalization rates in patients hospitalized for acute HF.7-10 In contrast, a number of 
other recent studies did not find any significant and independent association between diabetes status and 
mortality risk in this patient population.
11-16
 
 
Thus, all these findings clearly suggest that the prognostic value of diabetes per se on in‐hospital and 
post‐discharge survival outcomes in patients hospitalized for acute HF is still controversial. Currently, 
there is continued debate on this topic and, therefore, it warrants in‐depth investigation.  
 
The major aim of this study was to explore the rates of in‐hospital mortality, 1‐year all‐cause 
mortality, and 1‐year HF re‐hospitalization among the patients with and without diabetes, who were 
admitted to the hospital for acute HF, enrolled in the General Long‐term HF Registry that belongs to the 
EURObservational Research Programme (EORP) of the European Society of Cardiology (ESC) and the 
ESC‐Heart Failure Association (HFA).17 
  
Methods 
Study design 
The principles and procedures of the EORP of the ESC have been previously described.
17, 18
 Briefly, 
the ESC‐HF Long‐Term Registry is a prospective, multicentre, observational study of patients at 211 
Cardiology Centres in 21 European and Mediterranean countries, which are members of the ESC. The 
ESC‐HFA endorsed the study, which was conducted by an ad‐hoc Executive Committee.  
 
The national cardiology societies of each country agreed to participate in the programme and were 
asked to select hospitals of different levels of complexity from which patients could be recruited. The aim 
was to include a broad spectrum of cardiology and/or HF units following outpatients with HF and 
admitting patients with acute, worsening, or de novo HF to develop a network of centres that would be 
reasonably representative of the European reality. The number of participating centres for each country 
was decided according to the number of inhabitants in that country, i.e. one centre per 2 million people, 
but no more than 25 and no less than 6 per country. To the extent that it was possible, the centres were 
also chosen to fulfil geographical criteria within each country. In this way, the registry included a 
balanced proportion of centres with a range of cardiology facilities.  
 
The EORP Department at the ESC European Heart House was appointed to co‐ordinate the project's 
operations, to provide support to the committees, national co‐ordinators, and participating centres, and to 
oversee the methodological aspects of the survey. The database was established at the European Heart 
House, according to the requirements defined by the appointed Executive Committee with the support of 
the EORP Department. 
Patient population 
From May 2011 to April 2013, all outpatients seen at the clinics and all patients acutely admitted to 
the hospital for acute, worsening, or de novo HF were included in this registry during the enrolment 
period (on 1 day per week for 12 consecutive months). Therefore, on the screening day, the following 
patients were entered in the registry: (i) all outpatients with chronic HF diagnosed according to the 
clinical judgement of the responsible cardiologist at the participating centres; and (ii) all inpatients 
admitted to the hospital's cardiology ward or intensive cardiac care unit for acute HF, for whom an 
intravenous therapy (inotropes, vasodilators, or diuretics) was needed.  
 
There were no specific exclusion criteria, except for age ≤18 years. The registry was approved by each 
local Institutional Review Board according to the rules of each participating country. No data were 
collected before detailed information was provided to the patient and a signed informed consent was 
obtained. 
 
In the current analysis, we presented the 1‐year data from the ESC‐HF Long‐Term registry concerning 
the rates of in‐hospital mortality, 1‐year all‐cause and cardiac mortality, and 1‐year HF re‐hospitalization 
of patients who were admitted to hospital for acute, worsening, or de novo HF. Data on mortality were 
available for the whole cohort (n = 6926), whereas data on 1‐year HF re‐hospitalization were available in 
6540 (94.4%) participants.  
Diagnosis of diabetes 
Previously known diabetes was defined as self‐reported physician‐diagnosed diabetes, or use of 
medications for diabetes (insulin or oral hypoglycaemic agents). In the absence of previously known 
diabetes, the diagnosis of new‐onset diabetes was based on a fasting plasma glucose level ≥7.0 mmol/L 
(≥126 mg/dL) and/or a haemoglobin A1c (HbA1c) level ≥6.5%, respectively. In accord with the American 
Diabetes Association diagnostic criteria,
19
 only a plasma glucose level ≥200 mg/dL (≥11.1 mmol/L), in 
the presence of classical hyperglycaemic symptoms, is sufficient for the diagnosis of new‐onset diabetes 
without confirmation, whereas fasting glucose levels between 126 and 199 mg/dL (or an HbA1c ≥6.5%) 
are considered diagnostic for diabetes only if confirmed by at least two separate testings.  
Other clinical and laboratory data 
Body mass index (BMI) was calculated by dividing weight in kilograms by height in metres squared. 
Patients were considered as having hypertension if their blood pressure was ≥140/90 mmHg or if they 
were taking antihypertensive drugs. Serum creatinine, glucose, HbA1c, and other biochemical blood 
measurements were determined using local standard laboratory procedures. Estimated glomerular 
filtration rate (eGFR) was estimated using the four‐variable Modification of Diet in Renal Disease 
(MDRD) study equation.
20
 The presence of chronic kidney disease (CKD) was defined as an eGFRMDRD 
<60 mL/min/1.73 m2.20 Conventional trans‐thoracic echocardiography was used to measure the LV 
diameter, wall thickness, and EF according to international standard criteria.  
Statistical analysis 
The statistical analyses were performed at the ESC European Heart House. Categorical variables were 
reported and compared using a χ2 test or a Fisher's exact test if any expected cell count was <5. For 
categorical variables with more than two possible values, exact P‐values were estimated according to the 
Monte Carlo method. Continuous variables were reported either as means ± SD or as medians and 
interquartile range (IQR). Among‐group comparisons were made using a non‐parametric test (the 
Kruskal–Wallis test). Two multivariable regression models (model 1, adjusted for age, sex, systolic blood 
pressure, eGFRMDRD, LVEF, HF aetiology, and HF clinical presentation; and model 2, the same 
covariates included in model 1 plus BMI, smoking, hypertension, statin use, previous histories of stroke 
and COPD, sodium levels, and haemoglobin levels) were applied to estimate the risk associated with 
diabetes status at hospital admission in terms of in‐hospital mortality (by logistic regression analysis), 1‐
year all‐cause mortality, and 1‐year re‐hospitalization for HF (by Cox regression analysis). The covariates 
included in these multivariable regression models were chosen as potential confounding factors based on 
their significance in univariable analyses or their biological plausibility. We also examined the 
association between admission plasma glucose levels and the risk of adverse clinical outcomes after 
simultaneously stratifying the entire cohort of patients by quintiles of plasma glucose concentrations (i.e. 
∼1200 patients were included in each quintile) and by diabetes status. A two‐sided P‐value <0.05 was 
considered to be statistically significant. All analyses were performed with SAS statistical software 
version 9.4 (SAS Institute, Inc., Cary, NC, USA).  
Results 
As shown in Table 1, the study cohort included 6926 (63.0% men, mean age 69 years) hospitalized 
patients with acute HF, largely composed of overweight or obese individuals of Caucasian ancestry 
(∼83%). The prevalence of diabetes in the study cohort was high (n = 3422; 49.4%); 80.5% (n = 2755) of 
these patients had previously known diabetes (i.e. self‐reported history or use of hypoglycaemic drugs), 
whereas the remaining 667 (19.5%) patients had previously undiagnosed diabetes (as defined in the 
Methods). Among those with previously undiagnosed diabetes, 116 patients had a fasting glucose level 
≥200 mg/dL (i.e. a criterion sufficient for the diagnosis of diabetes without confirmation), whereas the 
remaining 549 patients had a fasting glucose level between 126 and 199 mg/dL, about one‐third of whom 
also had an HbA1c level ≥6.5%. So, similarly to other large registry databases like this, since repeat 
glucose testings were not available, we could not distinguish in a subgroup of ∼400 patients the exact 
number of those with a ‘true’ new diagnosis of diabetes from those with (non‐diabetic) transient stress 
hyperglycaemia during hospitalization. We were also unable to distinguish between type 1 and type 2 
diabetes mellitus, although the vast majority of our diabetic cases were likely to be type 2. 
Table 1. Baseline characteristics of the whole cohort of patients with acute heart failure stratified by diabetes status 
 
Diabetic patients (n = 3422)  Non‐diabetic patients (n = 3504)  P‐value  
    
Males 61.1% 64.8% 0.002 
Age (years) 70.0 ± 11.4 68.0 ± 14.4 <0.001 
Ethnic origin (Caucasian) 82.9% 82.2% 0.498 
BMI (kg/m2)  29.3 ± 5.4 27.7 ± 5.3 <0.001 
Systolic BP (mmHg) 134.9 ± 29.6 130.1 ± 27.3 <0.001 
Diastolic BP (mmHg) 79.2 ± 16.1 78.1 ± 15.4 0.002 
Total cholesterol (mg/dL) 164.6 ± 54.6 164.7 ± 50.8 0.400 
Heart rate (b.p.m,) 82.0 ± 20.6 80.5 ± 20.7 <0.001 
Plasma glucose (mg/dL) 168.8 ± 75.3 96.2 ± 14.2 <0.001 
Haemoglobin A1c 7.4 ± 3.8 5.6 ± 0.5 <0.001 
Hypertension 71.4% 57.6% <0.001 
Smoking status 15.7% 18.1% 0.007 
Diabetes medicationsa  
   
Insulin 52.5% 0.0% NA 
Oral hypoglycaemic drugs only 47.5% 0.0% NA 
Diet only 0.0% 0.0% NA 
Cardiovascular medications 
   
Statins 47.3% 36.8% <0.001 
ACE inhibitors or ARBs 73.4% 69.7% 0.002 
Beta‐blockers 62.8% 62.5% 0.809 
Aldosterone antagonists 36.6% 41.4% <0.001 
Diuretics 73.7% 71.5% 0.055 
Digitalis 20.0% 23.1% 0.005 
Calcium channel blockers 20.7% 14.0% <0.001 
Antiplatelets or anticoagulants 78.8% 75.7% 0.004 
Nitrates 30.6% 23.2% <0.001 
Amiodarone 10.0% 11.7% 0.037 
eGFRMDRD (mL/min/1.73 m
2)  54.9 ± 25.2 62.6 ± 34.7 <0.001 
eGFRMDRD <60 mL/min/1.73 m
2 61.3% 50.0% <0.001 
Haemoglobin (g/dL) 12.4 ± 2.2 12.7 ± 2.2 <0.001 
Sodium (mEq/L) 137.6 ± 5.4 138.3 ± 5.1 <0.001 
NT‐proBNP (pg/dL) 3900.0 (1674–9300) 3791.0 (1619–8878) 0.321 
LVEF (%) 39.2 ± 14.2 39.2 ± 14.5 0.971 
LVEF >45% 28.3% 31.2% 0.025 
NYHA class III–IV 86.8% 83.0% <0.001 
HF aetiology (ischaemic) 63.7% 49.0% <0.001 
HF (de novo)  28.5% 30.2% 0.118 
Atrial fibrillation 42.2% 45.0% 0.020 
COPD 21.8% 16.8% <0.001 
Previous stroke 13.7% 10.6% <0.001 
    
 
Data are expressed as means ± SD, medians (IQR), or percentages. 
Plasma glucose measurements were available in 5727 patients (n = 2969 and 2758 patients, respectively), whereas HbA1c and NT‐
proBNP measurements were available in a smaller group of patients (n = 1001 and 1499 patients, respectively).  
BMI, body mass index; BP, blood pressure; eGFRMDRD, estimated glomerular filtration rate (as calculated by the Modification of 
Diet in Renal Disease study equation); HF, heart failure; NA, not applicable.  
a Data on diabetes treatment were available for 3321 (97.1%) patients with diabetes.  
 
Table 1 shows the baseline characteristics of patients stratified by diabetes status at hospital 
admission. Mean plasma glucose levels were 168.8 ± 75 mg/dL in patients with diabetes and 
96.2 ± 14 mg/dL in those without diabetes, respectively. Mean HbA1c levels (available only in 1001 
participants; see footnote of Table 1) were 7.4 ± 3.8% in patients with diabetes and 5.6 ± 0.5% in those 
without. Patients with diabetes were more likely to be female, older, non‐smokers, obese, and 
hypertensive compared with those without diabetes. They also had a greater likelihood of ischaemic 
aetiology of HF, NYHA class III–V, CKD, prior stroke or COPD, but a lower prevalence of AF, and 
LVEF >45%. Moreover, patients with diabetes had lower levels of eGFRMDRD, haemoglobin, and sodium, 
and were more likely to be treated with statins, renin–angiotensin system blockers, calcium channel 
blockers, nitrates, antiplatelets or anticoagulants, and less likely to be treated with aldosterone 
antagonists, digitalis or amiodarone compared with those without diabetes. Most patients with diabetes 
were treated with insulin, oral hypoglycaemic drugs, or both. There were no significant differences in 
terms of ethnic origin, de novo HF presentation, beta‐blocker drug use, total cholesterol, and NT‐proBNP 
levels (available only in a subgroup of 1499 patients) between the two groups.  
 
Collectively, over the follow‐up period, there were 386 (5.6%) cases of in‐hospital mortality, 1781 
(25.7%) cases of 1‐year all‐cause mortality, 1001 (14.5%) cases of 1‐year cardiac mortality and 1361 
(20.8%) cases of 1‐year hospital re‐admission due to HF. 
 
As shown in Figure 1, the cumulative rates of in‐hospital mortality and 1‐year adverse clinical 
outcomes were markedly higher in patients with diabetes than in those without diabetes (P < 0.001 for all 
between‐group differences).  
 
 
 
Figure 1. Cumulative incidence rates of in‐hospital mortality, 1‐year all‐cause mortality, 1‐year cardiac mortality and 1‐year heart 
failure (HF) re‐hospitalization among patients admitted to the hospital for acute HF stratified by diabetes status. 
 
 
  
Table 2 shows the association between quintiles of plasma glucose levels at hospital admission and 
adverse clinical outcomes in the whole cohort of patients stratified by diabetes status. The rates per 100 
patient‐years of all considered clinical outcomes were almost always higher in patients with diabetes in 
each quintile of plasma glucose levels (i.e. at the same range of plasma glucose levels) than in those 
without diabetes. Elevated blood glucose levels at admission were associated with a significantly higher 
risk of in‐hospital mortality in both diabetic and non‐diabetic patients even after adjusting for age, sex, 
systolic blood pressure, eGFRMDRD, LVEF, HF aetiology, and HF presentation. In contrast, no significant 
associations were observed between admission blood glucose levels and 1‐year mortality or re‐
hospitalization rates in both groups of patients. 
Table 2. Association between plasma glucose quintiles at hospital admission and adverse outcomes in the whole cohort of patients 
stratified by diabetes status 
Group Outcome 
Plasma glucose 
(mg/dL) 
Events/patients 
Rate per 100 
patient‐years (95% 
CI) 
Unadjusted HR 
(95% CI) 
Adjusted HR 
(95% CI)a  
       
Diabetic 
patients 
1‐year all‐cause 
death 
≤90 72/231 31.2 (25.3–37.6) Reference Reference 
  >90–103 59/207 28.5 (22.5–35.2) 0.92 (0.65–1.30) 0.90 (0.59–1.40) 
  >103–122 91/339 26.8 (22.2–31.9) 0.82 (0.61–1.12) 0.91 (0.63–1.32) 
  >122–165 264/1048 25.2 (22.6–27.9) 0.81 (0.63–1.06) 0.81 (0.59–1.12) 
  >165 335/1144 29.3 (26.7–32.0) 0.96 (0.75–1.24) 1.10 (0.81–1.49) 
 1‐year 
cardiovascular 
death 
≤90 43/231 18.6 (13.8–24.2) Reference Reference 
  >90–103 37/207 17.9 (12.9–23.8) 0.97 (0.62–1.50) 0.74 (0.42–1.32) 
  >103–122 49/339 14.5 (10.9–18.7) 0.75 (0.50–1.13) 0.76 (0.47–1.23) 
  >122–165 151/1048 14.4 (12.3–16.7) 0.78 (0.56–1.10) 0.69 (0.46–1.03) 
  >165 205/1144 17.9 (15.7–20.3) 0.99 (0.71–1.37) 0.99 (0.68–1.45) 
 In‐hospital 
death 
≤90 7/231 3.0 (1.2–6.1) Reference Reference 
  >90–103 15/207 7.2 (4.1–11.7) 2.50 (1.00–6.25) 2.93 (0.84–
10.19) 
  >103–122 15/339 4.4 (2.5–7.2) 1.48 (0.59–3.69) 2.40 (0.74–7.75) 
  >122–165 78/1048 7.4 (5.9–9.2) 2.57 (1.17–5.65) 3.08 (1.07–8.84) 
  >165 94/1144 8.2 (6.7–10.0) 2.86 (1.31–6.25) 3.79 (1.33–
10.78) 
 1‐year HF re‐
hospitalization 
≤90 67/224 29.9 (24.0–36.4) Reference Reference 
  >90–103 57/192 29.7 (23.3–36.7) 0.99 (0.69–1.42) 1.01 (0.70–1.45) 
  >103–122 77/324 23.8 (19.2–28.8) 0.73 (0.52–1.02) 0.73 (0.52–1.03) 
  >122–165 230/970 23.7 (21.1–26.5) 0.77 (0.58–1.02) 0.82 (0.62–1.08) 
  >165 242/1050 23.0 (20.5–25.7) 0.75 (0.57–0.98) 0.85 (0.64–1.12) 
Non‐diabetic 
patients 
1‐year all‐cause 
death 
≤90 218/981 22.2 (19.7–25.0) Reference Reference 
  >90–103 184/903 20.4 (17.8–23.2) 0.89 (0.73–1.08) 0.78 (0.62–0.98) 
  >103–122 205/796 25.8 (22.7–28.9) 1.18 (0.97–1.42) 1.04 (0.83–1.30) 
  >122–165b  25/78 32.1 (21.9–43.6) 1.65 (1.09–2.49) 1.38 (0.82–2.30) 
  >165 0/0 NA NA NA 
 1‐year 
cardiovascular 
death 
≤90 125/981 12.7 (10.7–15.0) Reference Reference 
  >90–103 103/903 11.4 (9.4–13.7) 0.86 (0.67–1.12) 0.81 (0.60–1.08) 
Table 2. Association between plasma glucose quintiles at hospital admission and adverse outcomes in the whole cohort of patients 
stratified by diabetes status 
Group Outcome 
Plasma glucose 
(mg/dL) 
Events/patients 
Rate per 100 
patient‐years (95% 
CI) 
Unadjusted HR 
(95% CI) 
Adjusted HR 
(95% CI)a  
  >103–122 106/796 13.3 (11.0–15.9) 1.06 (0.82–1.37) 0.93 (0.69–1.25) 
  >122–165b  12/78 15.4 (8.2–25.3) 1.37 (0.76–2.47) 1.09 (0.53–2.24) 
  >165 0/0 NA NA NA 
 In‐hospital 
death 
≤90 31/981 3.2 (2.2–4.5) Reference Reference 
  >90–103 26/903 2.9 (1.9–4.2) 0.91 (0.54–1.54) 0.90 (0.52–1.55) 
  >103–122 38/796 4.8 (3.4–6.5) 1.54 (0.95–2.49) 1.41 (0.86–2.31) 
  >122–165* 7/78 9.0 (3.7–17.6) 3.02 (1.29–7.10) 2.82 (1.15–6.89) 
  >165 0/0 NA NA NA 
 1‐year HF re‐
hospitalization 
≤90 201/950 21.2 (18.6–23.9) Reference Reference 
  >90–103 174/877 19.8 (17.2–22.6) 0.91 (0.73–1.12) 0.80 (0.62–1.03) 
  >103–122 154/758 20.3 (17.5–23.4) 0.97 (0.78–1.21) 0.82 (0.63–1.07) 
  >122–165b  11/71 15.5 (8.0–26.0) 0.71 (0.36–1.38) 0.75 (0.33–1.71) 
  >165 0/0 NA NA NA 
       
 
Cohort size for this analysis, n = 5727.  
Cox regression analyses for 1‐year all‐cause death, 1‐year cardiovascular death, and 1‐year HF re‐hospitalization, and logistic 
regression analyses for in‐hospital death have been performed. CI, confidence interval; HF, heart failure; HR, hazard ratio; NA, not 
applicable. 
a Covariates considered for adjustment: age, sex, systolic blood pressure, estimated glomerular filtration rate (as calculated by the 
Modification of Diet in Renal Disease study equation), LVEF, HF aetiology and HF presentation.  
b Note that for non‐diabetic patients the maximum of plasma glucose levels in the fourth quintile was 125 mg/dL.  
Table S1 in the Supplementary material online shows the same associations between admission blood 
glucose levels and adverse clinical outcomes of those reported in Table 2. However, in this table, patients 
with diabetes were stratified by clinically chosen cut‐off levels (i.e. ≤125, 126–180, and >180 mg/dL), 
whereas patients without diabetes were stratified by tertiles of plasma glucose levels of the whole cohort 
of patients (i.e. ≤98, 98–132, and >132 mg/dL) at hospital admission. It is important to remark that, as 
expected, for patients without diabetes, the maximum plasma glucose level was 125 mg/dL. Also in this 
case, the rates per 100 patient‐years of all considered clinical outcomes were almost always higher in 
patients with diabetes than in those without diabetes in each cut‐off of admission plasma glucose levels. 
Similarly, elevated admission blood glucose levels were significantly associated with a higher in‐hospital 
mortality in patients with diabetes (and only marginally in patients without diabetes) after adjusting for 
age, sex, systolic blood pressure, eGFRMDRD, LVEF, HF aetiology, and HF presentation. No significant 
associations were observed between admission blood glucose levels and 1‐year follow‐up outcomes in 
both groups of patients.  
 
Table S2 in the Supplementary material online shows the age‐ and sex‐adjusted associations between 
diabetes treatment (insulin vs. diet/oral drugs) at hospital admission and adverse clinical outcomes in the 
subgroup of patients with diabetes. As expected, diabetic patients treated with insulin showed a worse 
prognosis than those treated with oral hypoglycaemic drugs or diet alone.  
 
Table 3 shows the effect of the adjustment for multiple potential confounding variables on the 
relationship between diabetes and in‐hospital mortality. Presence of diabetes was associated with an 
∼1.6‐fold increased risk of in‐hospital mortality after adjusting for age, sex, systolic blood pressure, 
eGFRMDRD, LVEF, HF aetiology, and HF presentation (model 1). Additional adjustment for other 
potential confounding variables (model 2) did not weaken the significant association between diabetes 
and in‐hospital mortality. Notably, other variables that were independently associated with in‐hospital 
mortality were older age, de novo HF presentation, lower BMI, lower systolic blood pressure (or a pre‐
existing non‐hypertensive status), lower LVEF, and lower levels of eGFRMDRD, haemoglobin, and 
sodium.  
Table 3. Multivariable logistic regression analysis for in‐hospital mortality in the whole cohort of patients 
Variables Regression model 1  Regression model 2 
 
OR (95% CI) P‐value  OR (95%CI) P‐value  
      
Diabetes status, yes vs. no 1.580 (1.177–2.120) 0.002  1.774 (1.282–2.456) <0.001 
Age, years 1.016 (1.003–1.028) 0.013  1.022 (1.008–1.036) 0.002 
Sex, male vs. female 0.910 (0.670–1.236) 0.545  0.868 (0.623–1.211) 0.406 
Systolic blood pressure, mmHg 0.974 (0.968–0.980) <0.001  0.980 (0.974–0.987) <0.001 
eGFRMDRD, mL/min/1.73 m
2 0.977 (0.971–0.984) <0.001  0.981 (0.973–0.988) <0.001 
LVEF, % 0.987 (0.976–0.998) 0.018  0.988 (0.977–1.000) 0.048 
HF aetiology, ischaemic vs. non‐ischaemic 0.814 (0.605–1.095) 0.173  0.926 (0.667–1.287) 0.648 
HF presentation, worsening vs. de novo 0.542 (0.401–0.733) <0.001  0.593 (0.422–0.833) 0.003 
BMI, kg/m2 NC   0.951 (0.919–0.984) 0.004 
Smoking status, yes vs. no NC   1.228 (0.796–1.895) 0.354 
Hypertension status, yes vs. no NC   0.645 (0.454–0.915) 0.014 
Statin use, yes vs. no NC   0.775 (0.556–1.082) 0.135 
Previous stroke, yes vs. no NC   1.472 (0.970–2.232) 0.069 
Previous COPD, yes vs. no NC   1.286 (0.894–1.850) 0.176 
Haemoglobin, g/dL NC   0.902 (0.841–0.968) 0.004 
Sodium, mEq/L NC   0.946 (0.925–0.967) <0.001 
      
 
Model 1: adjusted for age, sex, systolic blood pressure, eGFRMDRD, LVEF, HF aetiology, and HF presentation.  
Model 2: the same covariates included in model 1 plus BMI, smoking history, hypertension, statin use, previous stroke and COPD, 
haemoglobin, and sodium levels. 
BMI, body mass index; CI, confidence interval; eGFRMDRD, estimated glomerular filtration rate (as calculated by the Modification of 
Diet in Renal Disease study equation); HF, heart failure; NC, not considered; OR, odds ratio.  
Table 4 shows the effect of the adjustment for potential confounding variables on the relationship 
between diabetes and 1‐year all‐cause mortality. In regression model 2, the presence of diabetes was 
associated with a 1.16‐fold increased risk of 1‐year all‐cause mortality. Other variables that were 
independently associated with 1‐year all‐cause mortality were older age, male sex, prior stroke, non‐use 
of statins, lower systolic blood pressure (or a pre‐existing non‐hypertensive status), lower levels of 
eGFRMDRD, haemoglobin, and sodium, and lower LVEF. Similar findings were also observed for 1‐year 
cardiac mortality (data not shown). 
 
  
Table 4. Multivariable Cox regression analysis for 1‐year all‐cause mortality in the whole cohort of patients 
Variables Regression model 1  Regression model 2 
 
HR (95% CI) P‐value   HR (95% CI) P‐value  
      
Diabetes status, yes vs. no 1.133 (1.006–1.277) 0.040  1.162 (1.020–1.325) 0.024 
Age, years 1.029 (1.023–1.035) <0.001  1.030 (1.024–1.036) <0.001 
Sex, male vs. female 1.125 (0.988–1.280) 0.076  1.216 (1.058–1.399) 0.006 
Systolic blood pressure, mmHg 0.991 (0.989–0.993) <0.001  0.995 (0.992–0.997) <0.001 
eGFRMDRD, mL/min/1.73 m
2 0.986 (0.984–0.989) <0.001  0.989 (0.986–0.992) <0.001 
LVEF, % 0.985 (0.980–0.989) <0.001  0.984 (0.979–0.989) <0.001 
HF aetiology, ischaemic vs. non‐ischaemic 0.848 (0.750–0.958) <0.008  0.928 (0.812–1.060) 0.271 
HF presentation, worsening vs. de novo 1.027 (0.898–1.176) 0.695  1.106 (0.952–1.286) 0.189 
BMI, kg/m2 NC   0.987 (0.974–1.001) 0.061 
Smoking status, yes vs. no NC   0.926 (0.763–1.123) 0.432 
Hypertension status, yes vs. no  NC   0.742 (0.636–0.866) <0.001 
Statin use, yes vs. no NC   0.733 (0.640–0.840) <0.001 
Previous stroke, yes vs. no NC   1.260 (1.059–1.498) 0.009 
Previous COPD, yes vs. no NC   1.157 (0.994–1.348) 0.060 
Haemoglobin, g/dL NC   0.897 (0.871–0.923) <0.001 
Sodium, mEq/L NC   0.970 (0.961–0.980) <0.001 
      
 
Model 1: adjusted for age, sex, systolic blood pressure, eGFRMDRD, LVEF, HF aetiology, and HF presentation.  
Model 2: the same covariates included in model 1 plus BMI, smoking history, hypertension, statin use, previous stroke and COPD, 
haemoglobin, and sodium levels. 
BMI, body mass index; CI, confidence interval; eGFRMDRD, estimated glomerular filtration rate (as calculated by the Modification of 
Diet in Renal Disease study equation); HF, heart failure; HR, hazard ratio; NC, not considered.  
Table 5 shows the effect of the adjustment for multiple potential confounding variables on the 
relationship between diabetes and 1‐year re‐hospitalization for HF. Also in this case, the presence of 
diabetes was associated with a 1.32‐fold increased risk of 1‐year hospital re‐admission due to HF, 
independently of multiple potential confounders (model 2). Other variables that were independently 
associated with HF hospital re‐admissions were prior stroke, COPD, non‐ischaemic HF aetiology, lower 
systolic blood pressure, lower eGFRMDRD, lower haemoglobin, lower LVEF, and worsening HF 
presentation. 
  
Table 5. Multivariable Cox regression analysis for 1‐year heart failure re‐hospitalization in the whole cohort of patients 
Variables Regression model 1  Regression model 2 
 
HR (95% CI) P‐value   HR (95% CI) P‐value  
      
Diabetes status, yes vs. no 1.348 (1.175–1.548) <0.001  1.320 (1.139–1.530) <0.001 
Age, years 1.002 (0.996–1.008) 0.519  1.000 (0.993–1.006) 0.904 
Sex, male vs. female 1.082 (0.931–1.257) 0.306  1.067 (0.911–1.251) 0.422 
Systolic blood pressure, mmHg 0.996 (0.993–0.998) 0.001  0.997 (0.994–0.999) 0.020 
eGFRMDRD, mL/min/1.73 m
2 0.991 (0.988–0.994) <0.001  0.991 (0.988–0.994) <0.001 
LVEF, % 0.991 (0.985–0.996) <0.001  0.989 (0.983–0.994) <0.001 
HF aetiology, ischaemic vs. non‐ischaemic 0.828 (0.720–0.953) 0.008  0.803 (0.691–0.933) 0.004 
HF presentation, worsening vs. de novo 2.070 (1.737–2.467) <0.001  1.854 (1.536–2.239) <0.001 
BMI, kg/m2 NC   0.996 (0.982–1.010) 0.589 
Smoking status, yes vs. no NC   0.940 (0.766–1.154) 0.554 
Hypertension status, yes vs. no NC   0.885 (0.740–1.059) 0.182 
Statin use, yes vs. no NC   1.163 (1.002–1.349) 0.046 
Previous stroke, yes vs. no NC   1.343 (1.105–1.632) 0.003 
Previous COPD, yes vs. no NC   1.333 (1.128–1.575) <0.001 
Haemoglobin, g/dL NC   0.961 (0.931–0.993) 0.018 
Sodium, mEq/L NC   1.001 (0.988–1.015) 0.853 
      
 
Model 1: adjusted for age, sex, systolic blood pressure, eGFRMDRD, LVEF, HF aetiology, and HF presentation.  
Model 2: the same covariates included in model 1 plus BMI, smoking history, hypertension, statin use, previous stroke and COPD, 
haemoglobin, and sodium levels. 
BMI, body mass index; CI, confidence interval; eGFRMDRD, estimated glomerular filtration rate (as calculated by the Modification of 
Diet in Renal Disease study equation); HF, heart failure; NC, not considered.  
Finally, we also performed some sensitivity analyses to assess the robustness of our observations. 
Supplementary material online, Table S3 shows the age‐ and sex‐adjusted associations between patients 
with reduced LVEF ≤45% or with LVEF >45% at hospital admission and the risk of adverse clinical 
outcomes stratified by diabetic status. Conversely, Supplementary material online, Table S4 shows the 
associations between patients with ischaemic or non‐ischaemic HF aetiology and the risk of adverse 
clinical outcomes stratified by diabetic status.  
 
As expected, patients with LVEF >45% at hospital admission had better clinical outcomes than those 
with reduced LVEF ≤45%, irrespective of pre‐existing diabetes. In contrast, there were no significant age‐ 
and sex‐adjusted associations between patients with ischaemic or non‐ischaemic HF aetiology and risk of 
adverse outcomes stratified by diabetic status. Notably, in both of these sensitivity analyses, the rates per 
100 patient‐years of adverse clinical outcomes were almost always higher in patients with diabetes than in 
those without diabetes, irrespective of either HF aetiology or the level of LVEF at hospital admission. 
  
Discussion 
In this prospective, observational registry of a large unselected European population of consecutive 
patients admitted to the hospital for acute HF, we observed: (i) a very high prevalence of known and 
previously undiagnosed diabetes among these patients (49.4%); (ii) higher rates of in‐hospital mortality, 
1‐year all‐cause and cardiac mortality, and 1‐year hospital readmission due to HF in patients with 
diabetes (especially in those treated with insulin that may reflect a greater disease severity) compared 
with those without diabetes; (iii) a significant association between diabetes and in‐hospital mortality and 
1‐year follow‐up outcomes even after adjusting for multiple established risk factors and potential 
confounding variables (including also HF aetiology, HF presentation, LVEF, haemoglobin, and 
eGFRMDRD); and (iv) a significant and independent association between high blood glucose levels at 
hospital admission and the risk of in‐hospital mortality in both patients with and without diabetes.  
 
Our findings provide a contemporary picture on short‐ and mid‐term adverse clinical outcomes of a 
large European cohort of acute HF patients with and without diabetes, outside the context of randomized 
clinical trials. In addition, our findings also shed light on the previously reported discrepant results (as 
discussed below) regarding the prognostic impact of diabetes per se on adverse clinical outcomes among 
inpatients with acute HF. In fact, to date, despite the high prevalence of diabetes among patients with 
acute HF (ranging from 30% to 50%),
1-3
 the association between diabetes and HF often remains under‐
recognized by clinicians, and there are conflicting data regarding the prognostic impact of diabetes per se 
on the risk of mortality and re‐hospitalizations, both in the short and mid term, among patients 
hospitalized for acute HF.   
 
Our findings expand previous observations supporting that patients with acute HF and diabetes have 
poor in‐hospital mortality and/or post‐discharge adverse outcomes compared with those without 
diabetes.
7, 9, 10
 However, our findings also contrast with those from other previously published studies. For 
instance, in a large retrospective cohort study of Scottish patients discharged from hospital with a 
diagnosis of acute HF between 1986 and 2003, the presence of diabetes was associated with a lower 
mortality at 30 days, but it was an independent predictor of higher mortality at 1 year.
8 
Similarly, the 
presence of diabetes did not independently predict in‐hospital mortality in the cohort of patients from the 
Acute Decompensated Heart Failure National Registry (ADHERE).
11 
However, the ADHERE registry did 
not address the impact of diabetes on post‐discharge outcomes as these data were not collected. The 
Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure 
(OPTIMIZE‐HF) registry showed that the presence of diabetes did not independently predict in‐hospital 
mortality, 60‐ to 90‐day post‐discharge mortality, or re‐hospitalizations.15 Moreover, Kosiborod et al. did 
not find any association between diabetes and 30‐day and 1‐year all‐cause mortality in elderly patients 
hospitalized with acute HF.
12
 Finally, the presence of diabetes was strongly associated with higher rates 
of in‐hospital mortality but it did not significantly predict 1‐year post‐discharge mortality or re‐
hospitalization rates in the cohort of 1176 inpatients from the Italian Network on HF (IN‐HF) Outcome 
registry.
16 
 
To date, studies of patients with acute HF that have also specifically examined the association 
between admission blood glucose levels and the rates of mortality and hospital readmission are limited 
and discrepant. Some studies did not find any association between elevated admission blood glucose 
levels and mortality, both in the short and long term.
12, 14, 21
 Our results are consistent with other 
observations suggesting that elevated admission blood glucose levels are a prognostic marker for in‐
hospital mortality in both patients with and without diabetes.
10, 22, 23
 For example, Sud et al.
22
 
demonstrated that mildly elevated hyperglycaemia was significantly associated with increased rates of 30‐
day all‐cause mortality and re‐hospitalizations in patients with acute HF. However, similarly to our 
findings, the association between admission blood glucose levels and mortality was no longer significant 
at 1 year among these patients, regardless of pre‐existing diabetes.22 Although additional studies are 
certainly needed, our findings further suggest that in‐hospital hyperglycaemia is a reliable marker of poor 
short‐term outcomes and mortality in patients with and without diabetes.24, 25 
  
Unfortunately, as specified in the Results, we cannot exactly distinguish in a certain number of our 
patients between those with newly diagnosed diabetes and those with non‐diabetic stress hyperglycaemia, 
as repeat glucose testings or extensive HbA1c measurements were not performed. However, it is known 
that a significant association between transient stress hyperglycaemia and adverse clinical outcomes does 
exist in the short term (e.g. a longer length of hospital stay, a higher admission rate to an intensive care 
unit, and a higher rate of in‐hospital mortality), but not in the longer term.24, 25 Thus, it is important to 
underline that some misclassification of new‐onset diabetes based on a single blood glucose measurement 
was likely in our clinical setting (i.e. some of our newly diagnosed diabetic inpatients might have 
transient stress hyperglycaemia). If so, this misclassification could have partly affected the assessment of 
the ‘true’ prevalence of diabetes and its prognostic effect on in‐hospital mortality; in contrast, given that 
in the literature, transient stress hyperglycaemia has not been reported to be significantly associated with 
adverse clinical outcomes in the longer term,
24, 25
 our results are most likely to be a conservative estimate 
of the impact of diabetes on 1‐year clinical outcomes.  
 
The major strengths of our study are intrinsic to the design of the ESC‐HF Long‐Term Registry, 
which is one of the largest, multinational, and nationally representative systematic collections of 
contemporary European patients with HF. The sample size of our registry provides an adequate statistical 
power to keep the possible occurrence of both type I and type II errors to a minimum. Thus, we believe 
that the added value of our registry to the existing literature is that it provides solid and updated data 
regarding in‐hospital and 1‐year survival rates in a large unselected cohort of acute HF patients followed 
by cardiologists, thus providing a picture of European patients, who were not included in controlled trials 
but were currently being treated in general cardiology clinical practice. In addition, our registry also 
provides clear evidence of the impact of diabetes per se on the risk of both in‐hospital mortality and 1‐
year follow‐up outcomes as well as the possible impact of elevated blood glucose levels at hospital 
admission on the risk of in‐hospital mortality, regardless of pre‐existing diabetes. Finally, in our registry, 
thorough sensitivity analyses that accounted for a reasonably large number of established risk factors 
were also possible because of the availability of systematically collected clinical data, laboratory 
measures, and instrumental data (including echocardiographic functional measures, i.e. LVEF) for a large 
number of patients.  
 
Some important limitations of this registry should also be mentioned. First, although we sought to 
balance the methodological need for consecutiveness of enrolment with the practical feasibility, thereby 
decreasing the workload for centres by limiting recruitment to 1 day per week for 12 months, we cannot 
prove definitely the consecutiveness of patient enrolment. However, local audits were performed to verify 
the quality of data and the consecutiveness of enrolment. Secondly, representativeness is often recognized 
as a limitation in all observational studies. To lessen this problem, the centres were selected in proportion 
to the population size of participating countries, taking into account the different technological levels of 
the invited centres. Thirdly, all patients were enrolled in cardiology wards and clinics, and they do not 
represent those acutely admitted to other hospital facilities. Accordingly, our patient cohort does not 
represent the whole gamut of patients with acute HF. Fourthly, as discussed above, this study cannot 
exactly distinguish between a new diagnosis of diabetes and transient stress hyperglycaemia in a 
subgroup of patients. However, we would like to note that this is an intrinsic limitation of most 
epidemiological studies or registry databases, like this, in which the confirmation of diabetes diagnosis, 
on at least two separate occasions, in patients with previously undiagnosed diabetes has never been made. 
Finally, we lacked detailed information about the use of different classes of oral hypoglycaemic agents, 
the hypoglycaemic events, and the extra‐cardiac causes of mortality and re‐hospitalization, and also 
follow‐up data on plasma glucose and HbA1c levels were not available.  
 
In conclusion, our contemporary results from the ESC‐HF Long‐Term Registry show that the presence 
of diabetes is associated with substantially increased rates of in‐hospital mortality, 1‐year all‐cause 
mortality, and 1‐year HF re‐hospitalization in patients hospitalized for acute HF. Notably, these 
associations remain statistically significant after adjusting for multiple clinical risk factors and potential 
confounding variables (including also HF aetiology, HF presentation, LVEF, and kidney function 
parameters). Furthermore, elevated admission blood glucose concentrations are powerfully prognostic for 
in‐hospital mortality in patients both with and without established diabetes. In an era where there is 
increasing emphasis on chronic disease management as a strategy to contain healthcare costs, these 
findings further highlight the prognostic value of diabetes and the need for therapies that improve survival 
outcomes in this particularly high‐risk patient population.26 
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